Lumiracoxib

Lumiracoxib is an amino acid that is phenylacetic acid that is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity. Among its listed roles, it functions as a non-steroidal anti-inflammatory drug and a cyclooxygenase 2 inhibitor. It is a monocarboxylic acid, an amino acid, an organochlorine compound, an organofluorine compound and a secondary amino compound. It is grouped under the following drug class(es): Cyclooxygenase‑2 (COX‑2) Inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAID). Its therapeutic use is listed as antirheumatic agents. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include lumiracoxibum and Prexige. Its PubChem CID is 151166.

CAS No 220991-20-8
Molecular Formula C15H13ClFNO2
Molecular Weight 293.72 g/mol
Synonyms 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid

Frequently Asked Questions